Abstract
Diabetes is a major cause of mortality and morbidity due to the long term microvascular complications of this disease. There is now convincing evidence to show that genetic factors together with elevated blood glucose play an important role in the susceptibility to diabetic nephropathy as well as retinopathy. The polyol pathway is thought to play an important role in the pathogenesis of diabetic microvascular complications. Aldose reductase is the first and rate-limiting enzyme of the polyol pathway. Polymorphisms in the promoter region as well as elsewhere in the gene have been associated with susceptibility to nephropathy, retinopathy as well as diabetic neuropathy. These associations have been replicated in patients with either type 1 or type 2 diabetes mellitus as well as across ethnic groups. These polymorphisms in the promoter region are also associated with expression of the gene. Although clinical trials using inhibitors of aldose reductase to treat diabetic microvascular complications have largely been unsuccessful, the identification of the susceptibility genes may help in the design of future drug regimens.
Keywords: diabetic nephropathy, retinopathy, neuropathy, diabetes, aldose reductase, polyol pathway, genetics
Current Medicinal Chemistry
Title: Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications
Volume: 10 Issue: 15
Author(s): A. G. Demaine
Affiliation:
Keywords: diabetic nephropathy, retinopathy, neuropathy, diabetes, aldose reductase, polyol pathway, genetics
Abstract: Diabetes is a major cause of mortality and morbidity due to the long term microvascular complications of this disease. There is now convincing evidence to show that genetic factors together with elevated blood glucose play an important role in the susceptibility to diabetic nephropathy as well as retinopathy. The polyol pathway is thought to play an important role in the pathogenesis of diabetic microvascular complications. Aldose reductase is the first and rate-limiting enzyme of the polyol pathway. Polymorphisms in the promoter region as well as elsewhere in the gene have been associated with susceptibility to nephropathy, retinopathy as well as diabetic neuropathy. These associations have been replicated in patients with either type 1 or type 2 diabetes mellitus as well as across ethnic groups. These polymorphisms in the promoter region are also associated with expression of the gene. Although clinical trials using inhibitors of aldose reductase to treat diabetic microvascular complications have largely been unsuccessful, the identification of the susceptibility genes may help in the design of future drug regimens.
Export Options
About this article
Cite this article as:
Demaine G. A., Polymorphisms of the Aldose Reductase Gene and Susceptibility to Diabetic Microvascular Complications, Current Medicinal Chemistry 2003; 10 (15) . https://dx.doi.org/10.2174/0929867033457359
DOI https://dx.doi.org/10.2174/0929867033457359 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [ Hot Topic: Current Topics on the Epidemiology, Pathogenesis, and Treatment of Diabetes Mellitus and its Complications (Guest Editors: Moses S. Elisaf and Evangelos C. Rizos)]
Current Vascular Pharmacology The Role of Chronic Periodontitis in Prevention and Treatment of Head and Neck Cancers
Current Cancer Therapy Reviews Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets Association of Soluble Adhesion Molecule and C-Reactive Protein Levels with Silent Brain Infarction in Patients with and Without Type 2 Diabetes
Current Neurovascular Research Diabetes, Diabetic Complications, and Phosphate Toxicity: A Scoping Review
Current Diabetes Reviews Natural Alkaloids and Diabetes Mellitus: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Antiretroviral Drugs and The Kidney: Dosage Adjustment and Renal Tolerance
Current Pharmaceutical Design Renoprotection and Mechanisms of Erythropoietin and Its Derivatives Helix B Surface Peptide in Kidney Injuries
Current Protein & Peptide Science Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina
Current Diabetes Reviews Editorial on the Occasion of the 20th Anniversary of Endocrine Metabolic Immune Disorders-Drug Targets Journal with a Kaleidoscopic Vision of Selected Publications
Endocrine, Metabolic & Immune Disorders - Drug Targets Leukocyte-Independent Effects of CC-Chemokines on Vascular Remodeling
Current Pharmaceutical Biotechnology Ethnomedicinal Plants for the Management of Diabetes Worldwide: A Systematic Review
Current Medicinal Chemistry Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Flavonoids as Potential Therapeutic Agents for the Management of Diabetic Neuropathy
Current Pharmaceutical Design Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Neuronal and Glial Cell Abnormality as Predictors of Progression of Diabetic Retinopathy
Current Pharmaceutical Design Obesity and Arterial Compliance Alterations
Current Vascular Pharmacology A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin
Current Drug Targets